<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Book Index: Pulmonary Arterial Hypertension and Interstitial Lung Diseases</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="pulmonary-hypertension-ch11.html" class="nav-button"> 
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 100%;"></div> <!-- (13/13) * 100 -->
                        </div>
                       <span class="progress-text">Section 13 of 13</span> 
                    </div>
                    <a href="#" class="nav-button disabled"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Index (from PDF)</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <!-- START: book-index -->
                <section id="book-index" class="content-section" aria-labelledby="section-heading-book-index">
                    <div class="content-card">
                        <p><strong>A</strong></p>
                        <p>Acute rejection (AR), 124, 126</p>
                        <p>Acute respiratory distress syndrome (ARDS), 161, 166</p>
                        <p>American College of Chest Physicians (ACCP), 96-97</p>
                        <p>American Thoracic Society/European Respiratory Society, 3, 79-80</p>
                        <p>Anticardiolipin antibodies, in PPH, 95</p>
                        <p>Antineutrophil cytoplasmic antibody (ANCA) test, 82, 159, 170-171</p>
                        <p>Antinuclear antibodies (ANAs), 163, 168</p>
                        <p>Ardystil syndrome. See Textile sprayers lung</p>
                        <p>Arterial hypoxia, 21</p>
                        <p>Asbestosis</p>
                        <p>    diagnosis, 198</p>
                        <p>    symptom, primary, 197-198</p>
                        <p>    types, 196-197</p>
                        <p>Atrial natriuretic peptide (ANP), 15, 19, 22</p>
                        <p>Azathioprine, sarcoidosis drug, 231</p>
                        <p><strong>B</strong></p>
                        <p>BAL. See Bronchoalveolar lavage</p>
                        <p>Black lung disease. See Coal workers' pneumoconiosis (CWP)</p>
                        <p>Bone morphogenetic protein factor receptor type 2 gene (BMPR2), 13, 90</p>
                        <p>Bosentan therapy, 99-100</p>
                        <p>Brain natriuretic peptide (BNP), 181</p>
                        <p>    receiver operating characteristic analysis, 184</p>
                        <p>Bronchiolar disorders</p>
                        <p>    anatomy and definition, 109</p>
                        <p>    causes of, 109</p>
                        <p>    classification schema, 109-110</p>
                        <p>    CT patterns, classification, 116</p>
                        <p>    histopathology, 111-116</p>
                        <p>    radiographic features of, 117</p>
                        <p>Bronchiolectasis/Bronchiectasis, 161, 163</p>
                        <p>Bronchiolitis</p>
                        <p>    cardinal HRCT features of, 116</p>
                        <p>    cellular, 111</p>
                        <p>    cicatricial, 114</p>
                        <p>    clinical classification of, 110</p>
                        <p>    follicular, 115</p>
                        <p>    histopathological classification of, 113</p>
                        <p>    infectious, 111</p>
                        <p>Bronchiolitis obliterans, flavoring-related, 207</p>
                        <p>Bronchiolitis obliterans organizing pneumonia (BOOP), 113, 118</p>
                        <p>Bronchiolitis obliterans syndrome (BOS)</p>
                        <p>    clinical course and features of, 126</p>
                        <p>    diagnosis of, 125</p>
                        <p>    gastroesophageal reflux (GER) and, 127</p>
                        <p>    lung transplantation and complications, 124</p>
                        <p>    risk factors</p>
                        <p>        acute rejection (AR), 124</p>
                        <p>        HLA mismatching, 124-125</p>
                        <p>    therapy for, 126-127</p>
                        <p>Bronchoalveolar lavage (BAL), 14, 24-25, 29-32, 41, 125-128, 141, 163-164, 168-169</p>
                        <p>    CD4:CD8 ratio, sarcoidosis, 216</p>
                        <p>    COP patients and, 121</p>
                        <p>    in HP diagnosis</p>
                        <p>        lymphocytes and neutrophils in, 148-149</p>
                        <p>        subacute patient, 149</p>
                        <p><strong>C</strong></p>
                        <p>Calcium-channel antagonists, 97-98</p>
                        <p>Calcium channel blockers (CCBs), 97-98</p>
                        <p>Caplan's syndrome, 201</p>
                        <p>Cemented carbides. See Hard metal disease</p>
                        <p>CFA. See Cryptogenic fibrosing alveolitis</p>
                        <p>Chest roentgenogram, sarcoidosis, 215, 222</p>
                        <p>    stage system, 217-218</p>
                        <p>Chronic beryllium disease (CBD)</p>
                        <p>    diagnosis and natural history of, 205</p>
                        <p>    pathogenesis and symptoms, 204</p>
                        <p>    radiographic changes, 204-205</p>
                        <p>CMV. See Cytomegalovirus</p>
                        <p>Coal workers' pneumoconiosis (CWP)</p>
                        <p>    diagnosis, chest CT, 202-203</p>
                        <p>    in rheumatoid arthritis, 201</p>
                        <p>    symptoms, 201-202</p>
                        <p>    treatment, 203</p>
                        <p>Collagen vascular diseases</p>
                        <p>    peribronchiolar and interstitial lymphoid follicles, 81</p>
                        <p>    pulmonary manifestation, 80</p>
                        <p>Connective tissue diseases (CTDs), 109, 115, 117-118, 123-124, 171</p>
                        <p>Constrictive/Obliterative bronchiolitis</p>
                        <p>    causes of, 123-124</p>
                        <p>    chronic lung allograft rejection, 123</p>
                        <p>Corticosteroids (CS), 121-123, 128</p>
                        <p>Crohn's disease, 231-232</p>
                        <p>Cryptogenic fibrosing alveolitis (CFA), 70</p>
                        <p>Cryptogenic organizing pneumonia (COP), 26, 28-30, 70, 74-75, 112-113, 117, 128</p>
                        <p>    bronchoalveolar lavage, 121</p>
                        <p>    clinical manifestations of, 119</p>
                        <p>    corticosteroids therapy, 121-122</p>
                        <p>    fibrosis, 120</p>
                        <p>    frontal chest radiograph, 120</p>
                        <p>    histologic features, 75</p>
                        <p>    pathogenesis, 121</p>
                        <p>    radiographic features, 119-120</p>
                        <p>    rapidly progressive, 122</p>
                        <p>CWP. See Coal workers' pneumoconiosis</p>
                        <p>Cytomegalovirus (CMV), 124</p>
                        <p><strong>D</strong></p>
                        <p>Dermatomyositis, 166</p>
                        <p>Desquamative interstitial pneumonia (DIP), 3, 14, 26-27, 70, 76</p>
                        <p>Diffuse alveolar damage (DAD), 122</p>
                        <p>Diffuse alveolar damage/acute interstitial pneumonia (DAD/AIP), 70</p>
                        <p>    histologic differential diagnosis, 78-79</p>
                        <p>    pathologic features, 78</p>
                        <p>Diffuse panbronchiolitis, 115</p>
                        <p>Diffusing capacity for carbon monoxide (DL${}_{\text{CO}}$), 120</p>
                        <p><strong>E</strong></p>
                        <p>Eisenmenger's syndrome, 20</p>
                        <p>Endothelin antagonists, bosentan therapy, 99-100</p>
                        <p>Eosinophilic pneumonia (EP), 29-30</p>
                        <p><strong>F</strong></p>
                        <p>Farmer's lung disease, 139</p>
                        <p>Follicular bronchiolitis, 115</p>
                        <p>Forced vital capacity (FVC), 120, 163-164, 177</p>
                        <p><strong>G</strong></p>
                        <p>Gastroesophageal reflux (GER), 127</p>
                        <p>Ground glass opacities (GGOs), 116, 119, 128</p>
                        <p><strong>H</strong></p>
                        <p>Hamman-Rich syndrome, 3</p>
                        <p>Hard metal disease, 206</p>
                        <p>Hematopoietic stem cell transplantation (HSCT), 109, 117, 123-124</p>
                        <p>    OB complications, 127-128</p>
                        <p>    OP complications, 128</p>
                        <p>Hereditary hemorrhagic teleangectasia lesions, 13</p>
                        <p>High-resolution computed tomography (HRCT), 3, 143, 218-219</p>
                        <p>    COP, 28</p>
                        <p>    in DIP, 27</p>
                        <p>    fibrosis score and survival prediction, 25</p>
                        <p>    ground-glass</p>
                        <p>        distribution, 26</p>
                        <p>        opacity, 24</p>
                        <p>    ILD diagnosis and, 23</p>
                        <p>    in NSIP, 27</p>
                        <p>    role in diagnosis, 147-148</p>
                        <p>    in UIP, 26</p>
                        <p>Human leukocyte antigen (HLA), 124-125</p>
                        <p>Hypersensitivity pneumonitis (HP)</p>
                        <p>    acute and subacute, 142</p>
                        <p>    agents causing, 140</p>
                        <p>    chronic pulmonary fibrosis, 143</p>
                        <p>    diagnostic appraisal</p>
                        <p>        bronchoalveolar lavage (BAL), 148-149</p>
                        <p>        HRCT in, 147-148</p>
                        <p>        IgG antibodies, 148</p>
                        <p>        inhalation challenge test, 151</p>
                        <p>        lung biopsy, 149-152</p>
                        <p>        lymphocyte proliferation, antigeninduced, 149</p>
                        <p>    hemodynamic measurements</p>
                        <p>        echocardiography, 146-147</p>
                        <p>        lung inflammation/fibrosis effects, 145</p>
                        <p>    high-resolution computed tomography (HRCT), 143</p>
                        <p>    pathogenic mechanisms, 141</p>
                        <p>    physiological abnormalities, 145</p>
                        <p>    treatment and prognosis, 151, 153</p>
                        <p>Hypoxic pulmonary vasoconstriction (HPV), 15-16</p>
                        <p><strong>I</strong></p>
                        <p>Idiopathic interstitial pneumonia (IIP), 3, 70</p>
                        <p>Idiopathic pulmonary artery hypertension (IPAH). see Primary Pulmonary Hypertension (PPH)</p>
                        <p>Idiopathic pulmonary fibrosis (IPF), 4, 160, 221</p>
                        <p>    diagnosis, 7-8</p>
                        <p>    epidemiology of, 7</p>
                        <p>    mortality rates, 8</p>
                        <p>    pathogenesis, 185-186</p>
                        <p>    prediction, 182</p>
                        <p>        brain natriuretic peptide (BNP), 184-185</p>
                        <p>        pulmonary artery pressures, 183</p>
                        <p>        spirometry and DLco values, 183-184</p>
                        <p>    prevalence / incidence, 177-180</p>
                        <p>        echocardiographic data, 179</p>
                        <p>        right heart catheterization (RHC), 180</p>
                        <p>    prognostic influence, 180</p>
                        <p>        brain natriuretic peptide (BNP), 181-182</p>
                        <p>        Kaplan-Meier survival curves, 181</p>
                        <p>    pulmonary hypertension (PH), 177</p>
                        <p>    therapeutic approach</p>
                        <p>        epoprostenol infusion, 188</p>
                        <p>        hypoxia role, 186</p>
                        <p>        intervention studies of, 187</p>
                        <p>        lung transplantation, 190</p>
                        <p>        sildenafil effects, 188-190</p>
                        <p>        vasodilators use, 186, 188</p>
                        <p>Infliximab, sarcoidosis, 232</p>
                        <p>International Society of Heart Lung Transplantation (ISHLT), 124-125</p>
                        <p>Interstitial lung diseases (ILDs), 69, 88</p>
                        <p>    acute-onset, 30</p>
                        <p>    BAL, clinical role of, 29-30</p>
                        <p>    biopsies usage in, 10</p>
                        <p>    classification of, 4</p>
                        <p>    clinical assessment, 4-5</p>
                        <p>    diagnostic procedures, 9</p>
                        <p>    diagnostic tests, 45</p>
                        <p>    epidemiology, Europe vs. USA</p>
                        <p>        limitations and diagnosis, 5-6</p>
                        <p>        prevalence rates and incidence rates of, 5</p>
                        <p>        subgroups, 7-9</p>
                        <p>    epidemiology, occupational etiologies</p>
                        <p>        bronchiolitis obliterans, inducing chemicals, 207</p>
                        <p>        fibrous dust, 196-199</p>
                        <p>        granuloma-forming metals, 205-206</p>
                        <p>        metals, 204-205</p>
                        <p>        nonfibrous dust, 199-203</p>
                        <p>        occupational dust and sarcoidosis, 203</p>
                        <p>    epithelial cell injury and growth factors acumulation, 22</p>
                        <p>    fibrosis and, 22</p>
                        <p>    genetic factors</p>
                        <p>        mutations, pulmonary hypertension (PH) related, 13</p>
                        <p>        surfactant protein C, absence / abnormal production of, 14-15</p>
                        <p>    heart and lung correlation, 39-40</p>
                        <p>    interstitial lung process, 41</p>
                        <p>    IPF and</p>
                        <p>        honeycombing, 24-25</p>
                        <p>        patients, 15</p>
                        <p>    Kaplan Meyer survival, 44</p>
                        <p>    treatment, 162</p>
                        <p><strong>K</strong></p>
                        <p>KL-6 glycoprotein, 163</p>
                        <p><strong>L</strong></p>
                        <p>Leflunomide, sarcoidosis drug, 231</p>
                        <p>Lung and heart lung transplantation, 100-102</p>
                        <p>Lung transplantation (LT), 122-124, 126-128</p>
                        <p>Lung transplant recipients (LTRs), 109, 122-127</p>
                        <p>    OP complications, 122-123</p>
                        <p>    surveillance bronchoscopy, 124</p>
                        <p>Lupus pernio, sarcoidosis, 227</p>
                        <p>Lymphocytic interstitial pneumonia (LIP), 70, 79, 169</p>
                        <p><strong>M</strong></p>
                        <p>MAC. See Mycobacterium avium complex</p>
                        <p>Maximum midexpiratory flow rates (MMEF${}_{25-75}$), 125</p>
                        <p>Mean pulmonary artery (PAPm), 87</p>
                        <p>Methotrexate, sarcoidosis drug, 229</p>
                        <p>Microscopic polyangiitis (MPA), 171</p>
                        <p>Mineral dust airways disease, 115</p>
                        <p>6-minute walk test (6MWT)</p>
                        <p>    and interstitial lung disease, 28, 42, 45, 221, 233</p>
                        <p>    NYHA functional classes II, III, and IV, 99</p>
                        <p>Misguided angiogenesis, 21</p>
                        <p>Mycobacterium avium complex (MAC), 139</p>
                        <p>Mycobacterium tuberculosis, Sarcoidosis, 214</p>
                        <p>Mycophenolate mofetil drug, systemic sclerosis, 164</p>
                        <p><strong>N</strong></p>
                        <p>National Institutes of Health Registry, 87</p>
                        <p>New York Heart Association (NYHA), 42-45, 89, 93-94</p>
                        <p>    functional class of, 99</p>
                        <p>    sildenalafil in, 100</p>
                        <p>Nonspecific interstitial pneumonia ( NSIP), 3, 14, 24-27, 29, 34-35, 70</p>
                        <p>    differential diagnosis, 74</p>
                        <p>    pathologic features</p>
                        <p>        cellular pattern, 73</p>
                        <p>        fibrosing pattern, 74</p>
                        <p>Nonspecific interstitial pneumonitis, 161, 163, 169</p>
                        <p><strong>O</strong></p>
                        <p>Obliterative bronchiolitis (OB), 123-124</p>
                        <p>    examples of, 113</p>
                        <p>Octreoscan</p>
                        <p>    NSIP and, 35</p>
                        <p>    Octreoscan uptake index (UI)</p>
                        <p>        in NSIP, 34</p>
                        <p>        sarcoidosis and, 32-34</p>
                        <p>        in UIP and ILD, 34</p>
                        <p>    sarcoidosis, 36-37</p>
                        <p>    UIP and, 38</p>
                        <p>Organic dust toxic syndrome (ODTS), 142</p>
                        <p>Organizing pneumonia (OP), 110-114, 117, 119, 127-128</p>
                        <p>    complications</p>
                        <p>        collagen vascular disorders, 123</p>
                        <p>        inhalation injury, 123</p>
                        <p>        LT, 122-123</p>
                        <p>    CS therapy response, 121</p>
                        <p>    mosaic hypoperfusion, 119</p>
                        <p>    pulmonary consolidation, 118</p>
                        <p>    radiation therapy, complications</p>
                        <p>        migratory infiltrates, 122</p>
                        <p>    pattern</p>
                        <p>        causes of, 75</p>
                        <p>        polypoid plugs characterization of, 75</p>
                        <p><strong>P</strong></p>
                        <p>PAP. See Pulmonary artery pressure</p>
                        <p>Peribronchiolar fibrosis and bronchiolar metaplasia, 115-116</p>
                        <p>Phosphodiesterase inhibitors, sildenalafil in, 100</p>
                        <p>Pneumocystis carinii, 81</p>
                        <p>Polymyositis/dermatomyositis (PM/DM)</p>
                        <p>    autoantibodies, myositis-specific, 167</p>
                        <p>    diagnostic criteria, 166</p>
                        <p>    idiopathic inflammatory myopathies, 165</p>
                        <p>    muscle weakness, 166</p>
                        <p>Primary pulmonary hypertension (PPH), 87-89</p>
                        <p>    basic therapy</p>
                        <p>        calcium-channel antagonists, 97-98</p>
                        <p>        endothelin antagonists, 99-100</p>
                        <p>        phosphodiesterase inhibitors, 100</p>
                        <p>        prostanoids, 98-99</p>
                        <p>    cardiopulmonary testing algorithm, 94-95</p>
                        <p>    classification of, 90</p>
                        <p>    diagnosis, 90</p>
                        <p>    diagnostic algorithm for, 94</p>
                        <p>    epidemiology</p>
                        <p>        fenfluramine derivatives, pulmonary vascular effects, 90</p>
                        <p>        postmortem diagnosis, 89</p>
                        <p>    natural history of, 93-94</p>
                        <p>    pathophysiology, 90</p>
                        <p>        bone morphogenetic protein type-2 receptor (BMPR2) mutations, 91</p>
                        <p>        schematic view, 92</p>
                        <p>    pulmonary angiography, 95-96</p>
                        <p>    surgical treatment, 100-102</p>
                        <p>    symptoms of, 91-93</p>
                        <p>    treatment, 96-97</p>
                        <p>    variants and overlap PH syndromes, 102-103</p>
                        <p>Progressive massive fibrosis (PMF)</p>
                        <p>    International Labor Organization definition of, 200</p>
                        <p>    lesions, 201</p>
                        <p>Propionibacterium acnes, sarcoidosis, 214</p>
                        <p>Prostanoids</p>
                        <p>    epoprostenol, 98-99</p>
                        <p>    treprostenil, 99</p>
                        <p>Pseudomonas aeruginosa, 115</p>
                        <p>Pulmonary arterial hypertension (PAH), 4, 145, 164-165</p>
                        <p>    ACCP guidelines for, 100</p>
                        <p>    systemic lupus erythematosus and, 169</p>
                        <p>    treatment algorithm for, 101</p>
                        <p>Pulmonary artery pressure (PAP), 19</p>
                        <p>    correlation, 42-43</p>
                        <p>    diagnosis, 43</p>
                        <p>Pulmonary artery systolic pressure (PASP), 224-226</p>
                        <p>Pulmonary function tests</p>
                        <p>    chronic beryllium disease (CBD), 204</p>
                        <p>    silicosis, 200</p>
                        <p>    textile sprayers lung, 207</p>
                        <p>Pulmonary function tests (PFTs), 111, 114, 128</p>
                        <p>Pulmonary hypertension (PH)</p>
                        <p>    categories of, 19</p>
                        <p>    classification of, 88</p>
                        <p>    echocardiography, 40-41</p>
                        <p>    ILD physiology</p>
                        <p>        increased pulmonary vascular tone, causing factors of, 17</p>
                        <p>        lung zones, 15</p>
                        <p>        potassium channels, subtypes of, 16</p>
                        <p>        super oxide dismutase, blockage structure, 16</p>
                        <p>    latent and manifest, 19-20</p>
                        <p>    pathophysiology of, 17</p>
                        <p>        mechanisms of, 19</p>
                        <p>        right ventricular adaptation, 20</p>
                        <p>    severe/very severe</p>
                        <p>        adventitia and intima cells, 20-21</p>
                        <p>        blood vessels, static and hydrostatic forces, 21</p>
                        <p>        humoral mediators, 22</p>
                        <p>        interleukin, role of, 22-23</p>
                        <p>        plexogenetic arteriopathy, 21</p>
                        <p>        Th1 and Th2 cytokine production, 23</p>
                        <p>        vessel remodeling, 20</p>
                        <p>    symptoms and signs of, 93</p>
                        <p>    ventilation/perfusion (V/Q) scintigraphy, 95</p>
                        <p>Pulmonary vascular resistance index (PVRI), 188</p>
                        <p>Pulmonary veno-occlusive disease (PVOD), 96</p>
                        <p><strong>R</strong></p>
                        <p>Raynaud's phenomenon, Systemic Sclerosis (SSc), 162</p>
                        <p>Registro Italiano Pneumopatie Infiltrative Diffuse (RIPID), 5-6</p>
                        <p>Respiratory bronchiolitis (RB), 114</p>
                        <p>Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), 76-77</p>
                        <p>Respiratory syncytial virus (RSV), 111</p>
                        <p>Reynaud's phenomenon, 93</p>
                        <p>Rheumatoid arthritis (RA)</p>
                        <p>    airway diseases, 161</p>
                        <p>    diagnostic criteria for, 160</p>
                        <p>    dyspnea causing manifestations, 161</p>
                        <p>    etanercept, 231-232</p>
                        <p>    lung disease and, 162</p>
                        <p>    rheumatoid factor (RF) and, 160</p>
                        <p>Right heart catheterization (RHC), 180</p>
                        <p>    Kaplan-Meier survival curves, 181</p>
                        <p>Right ventricular ejection fraction (RVEF), 188</p>
                        <p>Right ventricular hypertrophy (RVH)</p>
                        <p>    electrocardiogram of, 94</p>
                        <p>Right ventricular systolic pressure (RVSP)</p>
                        <p>    echo Doppler for, 95</p>
                        <p>Rituximab antibody, Wegener Granulomatosis (WG), 170</p>
                        <p><strong>S</strong></p>
                        <p>Saint George Respiratory Questionnaire, sarcoidosis, 222</p>
                        <p>Sarafotoxin S6c, ET-1 receptors, 17</p>
                        <p>Sarcoidosis, 24, 28, 32-34, 36, 40</p>
                        <p>    CD4 + and CD8 + ratio29-30</p>
                        <p>    clinical and laboratory features, 216</p>
                        <p>    cutaneous, 217</p>
                        <p>    diagnosis of</p>
                        <p>        adenopathy, 216</p>
                        <p>        granulomas, 215</p>
                        <p>    epidemiology and etiology</p>
                        <p>        environmental agents, 215</p>
                        <p>        infectious agents, 214</p>
                        <p>        organ involvement, 213-214</p>
                        <p>    etiology of, 8-9</p>
                        <p>    octreoscan in, 33-34</p>
                        <p>    pulmonary assessment</p>
                        <p>        bilateral honeycombing, 219</p>
                        <p>        cardiopulmonary exercise tests, 221</p>
                        <p>        chest roentgenogram, 217-218, 222</p>
                        <p>        CT scan and, 221-222</p>
                        <p>        mean pulmonary function studies, 219</p>
                        <p>        muscle weakness, 218</p>
                        <p>        6MWT vs. pulmonary function and health assessment, 223</p>
                        <p>        obstructive lung disease, 220</p>
                        <p>        peribronchial thickening, 220</p>
                        <p>        X-ray stage, 218</p>
                        <p>    pulmonary hypertension, 226</p>
                        <p>        causes of, 224</p>
                        <p>        echocardiography, 224-225</p>
                        <p>        rate of, 224</p>
                        <p>    single-emission photon computed tomography, 37-38</p>
                        <p>    specific drug therapy for, 230</p>
                        <p>    treatment of patients</p>
                        <p>        chloroquine, 229</p>
                        <p>        chronic therapy, requirment, 228</p>
                        <p>        corticosteroids, 226, 229</p>
                        <p>        cytotoxic agents, 231</p>
                        <p>Sarcoidosis (cont.)</p>
                        <p>    evidence-based recommendations, 227-228</p>
                        <p>Sarcoidosis-associated pulmonary arterial hypertension (SAPAH)</p>
                        <p>    endothelin receptors, 233</p>
                        <p>    therapy results of, 233</p>
                        <p>Sauropus androgynus, 123-124</p>
                        <p>Scintigraphy/Gallium-67 and Indium-111 Octreotide Scan, 33-39</p>
                        <p>    somatostatin receptor imaging, 32</p>
                        <p>Shrinking lung syndrome, systemic lupus erythematosus (SLE), 168</p>
                        <p>Silicosis</p>
                        <p>    CT scans, 200-201</p>
                        <p>    diagnosis of, 201</p>
                        <p>    risk of, 199-200</p>
                        <p>    symptoms, 200</p>
                        <p>Sjögren syndrome (SS), 169-170</p>
                        <p>Surfactant protein/C (SP/C), 14</p>
                        <p>Surgical biopsies, 69</p>
                        <p>Systemic lupus erythematosus (SLE), 167</p>
                        <p>    acute lupus pneumonitis, 168</p>
                        <p>    alveolar hemorrhage, 169</p>
                        <p>    diagnostic criteria for, 168</p>
                        <p>    pleuritis, 168</p>
                        <p>Systemic scleroderma, 39, 42</p>
                        <p>Systemic Sclerosis (SSc)</p>
                        <p>    cutaneous variant, 162</p>
                        <p>    cyclophosphamide drugs, 164</p>
                        <p>    ILD and, 163</p>
                        <p>    pulmonary arterial hypertension (PAH) related, 164-165</p>
                        <p>    Scl-70 antibodies, 163</p>
                        <p>    SS variant, findings of, 162</p>
                        <p>Systolic pulmonary arterial pressure (sPAP), 40</p>
                        <p>    Kaplan-Meier survival curves, 181</p>
                        <p><strong>T</strong></p>
                        <p>Textile sprayers lung, 207</p>
                        <p>Thalidomide, cutaneous sarcoidosis, 231</p>
                        <p>T-lymphocyte, 141</p>
                        <p>Total lung capacity (TLC), 120</p>
                        <p>Transbronchial lung biopsies (TBBs), 114, 125</p>
                        <p>Tricuspid valve regurgitation (TR), 40, 45</p>
                        <p><strong>U</strong></p>
                        <p>Usual interstitial pneumonia (UIP), 3, 14, 25-26, 28, 69, 160-163, 169</p>
                        <p>    differential diagnosis, 73</p>
                        <p>    histologic features</p>
                        <p>        fibrosis photomicrograph, 71-72</p>
                        <p>        heterogeneity, 72</p>
                        <p>        honeycombing, 71</p>
                        <p>    octreoscan of, 38</p>
                        <p>    PAPs and NYHA class cases, survival, 44</p>
                        <p>    single-emission photon computed tomography, 39</p>
                        <p><strong>V</strong></p>
                        <p>Ventilation/perfusion (V/Q) scintigraphy, 95</p>
                        <p><strong>W</strong></p>
                        <p>Wegener granulomatosis (WG)</p>
                        <p>    aggressive therapy, 170-171</p>
                        <p>    differential diagnosis of, 82-83</p>
                        <p>    granulomatous vasculitis, 170</p>
                        <p>    staining patterns and histologic features of, 82</p>
                        <p>Westergren sedimentation rate test, rheumatoid disease, 162</p>
                    </div>
                </section>
                <!-- END: book-index -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="pulmonary-hypertension-ch11.html" class="nav-button"> 
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 100%;"></div> 
                        </div>
                       <span class="progress-text">Section 13 of 13</span> 
                    </div>
                    <a href="#" class="nav-button disabled"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script> 
</body>
</html>